Abbott Laboratories stock gained 2.67 percent ahead of results

Published on 10/06/2026 at 14:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock enters the October 21 results date with Q2 revenue of USD 12.593 billion, up 13 percent year over year. Adjusted EPS reached USD 1.31 versus USD 1.28 consensus.

Bauhaus MEDTECH DIAGNOSTIK Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 Bauhaus-Poster MEDTECH DIAGNOSTIK Geometrie Primärfarben Rot Gelb Blau Schwarz Kreise Dreiecke, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) gained 2.67 percent and closed at USD 100.10 on the NYSE on October 5, 2026. The move came as investors weighed the company’s October 21 date for fiscal Q3 2026 results against its latest quarterly figures.

October 21 results set the next test

Abbott’s Q2 2026 revenue reached USD 12.593 billion, while diluted GAAP EPS was USD 0.53, according to the company’s latest financial data for the quarter ended June 30, 2026. Operating profit was USD 1.693 billion and operating cash flow was USD 2.488 billion for the same period.

For the adjusted measure used in the earnings comparison, MarketBeat reported on October 2, 2026, that Q2 adjusted EPS was USD 1.31 versus USD 1.28 consensus. Revenue was USD 12.59 billion, up 13 percent from the prior-year quarter, giving the October release a higher bar for execution.

Redburn lifts its price target

Rothschild & Co Redburn upgraded Abbott from Neutral to Buy on October 2, 2026, and raised its price target from USD 119 to USD 127, according to MarketBeat. The new target is USD 26.90, or 26.9 percent, above the October 5 closing price.

The broader analyst view is less concentrated than the single-house action. MarketBeat described a Moderate Buy consensus on October 1, 2026, based on 27 ratings, with an average 12-month target of USD 119.50 and a published target range of USD 102 to USD 130. The average target stands 19.4 percent above the October 5 close.

Diagnostics adds a new growth angle

Abbott launched the FDA-approved SimpleScreen CRC blood test in the United States on September 30, 2026, according to Abbott. The test showed 81.1 percent overall sensitivity, 63.5 percent sensitivity for Stage I colorectal cancer and 90.4 percent specificity for advanced colorectal neoplasia in a study of more than 48,000 adults.

The product expands Abbott’s diagnostics portfolio alongside Cologuard Plus and is covered by Medicare for eligible Part B patients. That commercial addition gives the October 21 results a second checkpoint beyond the income statement.

Abbott stock closes at USD 100.10

Abbott Laboratories stock closed at USD 100.10 on the NYSE on October 5, 2026, with a 52-week range of USD 81.97 to USD 135.24 and market capitalization of USD 173.2 billion.